A new Harris Interactive poll shows a majority of American parents believe they, rather than the government, should have the final say in which vaccines their children receive.
A new Harris Interactive poll shows a majority of American parents believe they, rather than the government, should have the final say in which vaccines their children receive.
The poll, commissioned by the Center for Personal Rights, queried a representative sample of American parents about vaccination. The survey was conducted online in May within the United States by Harris Interactive on behalf of the Center for Personal Rights, Inc., among 1,144 parents of children age 17 years or younger.
Poll results indicate a majority of American parents, 52%, believe that "parents should have the right to decide which vaccines their children receive without government mandates."
Such results may stem from recent media reports, which have since been discredited, that vaccines do more harm than good, may cause autism, or are no longer necessary for certain diseases.
“In one warning after another, vaccine opponents often exaggerate or even make up immunization risks, with no scientific evidence to support their claims,” according to a statement on the American Academy of Pediatrics website. “They may imply that vaccines aren’t effective. At the same time, they downplay or don’t discuss the serious diseases that vaccines can eliminate or reduce in frequency. No wonder some parents are left feeling anxious and, in some cases, keep their youngster unvaccinated at the risk of their child’s health.”
But those assurances may be falling on deaf ears. Other results from the Center for Personal Rights, Inc. research include:
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen